Pharmaceuticals

MBX Biosciences

LifeSci Capital Analyst Patrick Dolezal Maintains Buy Rating on MBX Biosciences with $91 Target Price

MBX Biosciences shares fall but analysts raise price targets

MBX Biosciences released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5099 (forecast USD -0.5847)

MBX Biosciences CEO Buys Company Stock

MBX Biosciences released FY2025 earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.3823 (forecast USD -2.5309)

MBX Biosciences released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4907 (forecast USD -0.6339)

MBX Biosciences Publishes Corporate Presentation Detailing Drug Pipeline

MBX Biosciences Receives 'Moderate Buy' Analyst Consensus Rating

MBX Biosciences released FY2025 Q3 earnings on November 6, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6321 (forecast USD -0.6971)

MBX Biosciences released FY2025 9 Months earnings on November 6, 2025 (EST), actual revenue: USD 0, actual EPS: USD -1.9271

MBX Biosciences released FY2025 Semi-Annual Earnings on August 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.2949

MBX Biosciences released FY2025 Q2 earnings on August 7, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.5803 (forecast USD -0.7645)

MBX Biosciences released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7147 (forecast USD -0.7481)

MBX Biosciences released FY2024 Annual Earnings on March 17 (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -5.8181 (Forecast: USD -6.2051)

MBX Biosciences released FY2023 Q4 earnings on March 17 (EST) with actual revenue of 0 USD and EPS of -7.7261 USD

MBX Biosciences released FY2024 Q4 earnings on March 17 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.4667 USD (forecast -0.5646 USD)

MBX Biosciences released FY2024 9 Months Earnings on November 7 (EST), with actual revenue of 0 USD and EPS of -25.6641 USD

MBX Biosciences released FY2023 Q3 earnings on November 7, 2024 (EST), with actual revenue of 0 and EPS of -9.3975

MBX Biosciences released FY2023 9 Months Earnings on November 7, 2024 (EST) with actual revenue of 0 USD and EPS of -24.021 USD

MBX Biosciences released FY2024 Q3 earnings on November 7, 2024 (EST), with actual EPS of -2.7843 (forecasted -2.6016)

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

LABU

SBIO

MBX Biosciences reported a Q1 2026 net loss of $23.52 million and appointed Mark R. Soued as Chief Commercial Officer. Despite a 20.79% decline in share price, early obesity pipeline data shows promise. The company aims to build a differentiated obesity franchise, supported by a $440 million cash runway. However, insider selling and ongoing losses raise concerns for investors. Analysts suggest MBX may be overvalued based on its financials, while differing fair value estimates create uncertainty in its investment narrative.

Simplywall

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

SPDR S&P Biotech

MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed?

LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on MBX Biosciences, Inc. with a price target of $91.00. The analyst has an average return of 15.0% and a 43.63% success rate. The overall analyst consensus for MBX is a Strong Buy, with an average price target of $73.11.

Tip Ranks

iBio

Neurogene

Rocket Pharma

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)

MBX Biosciences (NASDAQ:MBX) shares fell 8.8% to $36.54 amid increased trading volume. Analysts remain optimistic, with Citizens JMP raising its price target to $86 and Truist Financial to $70, both maintaining positive ratings. The company reported promising Phase 1 data for its obesity drug, MBX-4291. Despite a mixed forecast from Lifesci Capital, the overall sentiment is bullish, with a consensus rating of "Moderate Buy" and an average target price of $60.22. CEO P. Kent Hawryluk recently increased his stake in the company, acquiring 18,500 shares.

Market Beat

MBX Biosciences (NASDAQ:MBX) Trading Down 8.8%  - Here's What Happened

IBBQ

ARKG

Interpace Biosciences reported Q1 2026 revenue of $9.0 million, a 12% increase in thyroid revenue year-over-year. The company achieved income from continuing operations of $0.8 million and an Adjusted EBITDA of $1.6 million, reflecting operational efficiency in its thyroid-only diagnostics model. Key highlights include a 3% increase in average thyroid revenue per test and a 21% improvement in turnaround time. The company reaffirms its 2026 guidance of approximately 16% year-over-year thyroid revenue growth, focusing on expanding its active account base and enhancing productivity through automation.

StockTitan

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results | IDXG Stock News

MBX Biosciences highlighted its lead obesity candidate MBX 4291 during its Obesity Day event, presenting preliminary clinical data and introducing a new preclinical program. The company aims for once-monthly dosing with MBX 4291, which showed promising weight loss results in early trials. Additionally, MBX introduced MBX 5765, an amycretin program, and discussed the growing obesity market, projected to exceed $90 billion by 2031. The company plans to begin a phase 3 study of canvuparatide soon and reported positive data for imapextide in post-bariatric hypoglycemia.

MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

MBX Biosciences(MBX.US)

MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed?

LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)

MBX Biosciences (NASDAQ:MBX) Trading Down 8.8% - Here's What Happened

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results | IDXG Stock News

MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push